Stealth BioTherapeutics Corp (MITO)

Etorro trading 970x250
Stealth BioTherapeutics Corp (MITO) Logo

About Stealth BioTherapeutics Corp

Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases. The company’s product candidates include SBT-20, a small peptide that targets and binds reversibly to cardiolipin, stabilizing mitochondrial structure, and function under conditions of oxidative stress; and SBT-272, a lead discovery pipeline compound, evaluating for rare neurodegenerative diseases, such as amyotrophic lateral sclerosis. Stealth BioTherapeutics Corp was founded in 2006 and is based in George Town, the Cayman Islands. Address: 190 Elgin Avenue, George Town, Cayman Islands, KY1-9005

Stealth BioTherapeutics Corp News and around…

Latest news about Stealth BioTherapeutics Corp (MITO) common stock and company :

12 Health Care Stocks Moving In Friday's Pre-Market Session
22 Oct, 2021 FinancialContent

Gainers Nutriband (NASDAQ:NTRB) shares rose 15.52% to $6.72 during Friday's pre-market session. The market value of ...

12 Health Care Stocks Moving In Wednesday's Intraday Session
20 Oct, 2021 FinancialContent

Gainers Sesen Bio (NASDAQ:SESN) stock increased by 29.2% to $1.3 during Wednesday's regular session. Trading volume ...

Stealth Bio Stock Falls On FDA Refusal to File Letter For Barth Syndrome Candidate
20 Oct, 2021 FinancialContent

Stealth BioTherapeutics Corp(NASDAQ: MITO) hasreceived a Refusal to File letter from the FDAregarding its marketing ...

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
20 Oct, 2021 FinancialContent

Gainers F-star Therapeutics (NASDAQ:FSTX) shares increased by 18.74% to $7.6 during Wednesday's pre-market session. ...

Stealth BioTherapeutics Receives Refusal to File Letter from the FDA
20 Oct, 2021 Yahoo! Finance

Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it received a Refusal to File letter from the United States Food and Drug Administration (FDA) regarding Stealth's New Drug Application (NDA) for elamipretide, a mitochondria-targeted therapy for the treatment of Barth syndrome.

The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
08 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Stealth BioTherapeutics Presents Positive SBT-272 Preclinical Data at 2021 Annual Northeast Amyotrophic Lateral Sclerosis (NEALS) Meeting
07 Oct, 2021 Yahoo! Finance

Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced today the presentation of new promising data from a study evaluating the effects of SBT-272 in a murine model of amyotrophic lateral sclerosis (ALS). The data were presented at the virtual 2021 Annual Northeast Amyotrophic Lateral Sclerosis (NEALS) Meeting held October 6-7, 20

The Petri Dish: Takeda taps Selecta for gene therapy, BICO makes another buy
06 Oct, 2021 Yahoo! Finance

While some in the life sciences industry create drugs and devices to tackle the Covid-19 pandemic, their colleagues are busy as ever raising money, testing new drugs, expanding facilities and more.

Horizon Technology Finance Provides Third Quarter 2021 Portfolio Update
06 Oct, 2021 Yahoo! Finance

Horizon Technology Finance Corporation (NASDAQ: HRZN) ("HRZN" or the "Company"), a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, healthcare information and services, and sustainability industries, today provided its portfolio update for the third quarter ended September 30, 2021 and an update on the lending platform ("Horizon Platform") of Horizon Technology Finance Management LLC ("HTFM")

Stealth BioTherapeutics Completes a $25 Million Debt Financing with Horizon Technology Finance
04 Oct, 2021 Yahoo! Finance

Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced completion of a $25 million long-term debt facility led by Horizon Technology Finance Corporation (Nasdaq: HRZN) ("Horizon"). Stealth has drawn down $15 million under the facility with an additional $10 million available upon achievement of a predetermined milestone.

Stealth Bio Posts Encouraging Preclinical Data In Parkinson's Animal Studies
23 Sep, 2021 FinancialContent

Stealth BioTherapeutics Corp(NASDAQ: MITO) haspresented new data from a studyevaluating SBT-272 in a murine model ...

Stealth BioTherapeutics Presents Positive SBT-272 Preclinical Data at International Parkinson and Movement Disorder Society Virtual Congress 2021
23 Sep, 2021 Yahoo! Finance

Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced today the presentation of new promising data from a study evaluating the effects of SBT-272 in a murine model of Parkinson's disease (PD). SBT-272 is a novel, clinical-stage mitochondria-targeted product candidate which is known to cross the blood-brain barrier. The data were

12 Health Care Stocks Moving In Thursday's After-Market Session
16 Sep, 2021 FinancialContent

Gainers Stealth BioTherapeutics (NASDAQ:MITO) stock rose 3.59% to $1.44 during Thursday's after-market session. The ...

38 Stocks Moving In Wednesday's Mid-Day Session
15 Sep, 2021 FinancialContent

Gainers Indaptus Therapeutics, Inc. (NASDAQ: INDP) shares jumped 177.2% to $19.60 after the company announced the United States ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
15 Sep, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investor! We're jumping back into the stock market as we take a look at the biggest pre-market stock movers for Wednesday. The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

26 Stocks Moving in Wednesday's Pre-Market Session
15 Sep, 2021 FinancialContent

Gainers Nxt-ID, Inc. (NASDAQ: NXTD) rose 46.1% to $0.6699 in pre-market trading after dropping 11% on Tuesday. MeaTech 3D Ltd. ...

Stealth BioTherapeutics to Showcase Leadership in Retinal Mitochondrial Health with Clinical Updates at Ophthalmic Conferences
14 Sep, 2021 Yahoo! Finance

Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced today that multiple abstracts have been accepted for presentation at several leading ophthalmic conferences this fall. These abstracts feature novel clinical findings from the positive ReCLAIM trial, which evaluated elamipretide in patients with dry age-related macular degener

Stealth BioTherapeutics to Present at Upcoming September Virtual Investor Conferences
07 Sep, 2021 Yahoo! Finance

Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCarthy, CEO, will present at two upcoming virtual investor conferences in September:

Stealth (MITO) Files NDA for Ultra-Rare Disease Candidate
25 Aug, 2021 Yahoo! Finance

Stealth BioTherapeutics (MITO) files a new drug application for elamipretide to the FDA for the treatment of Barth syndrome, an ultra-rare genetic condition.

Stealth Bio Files US Application For Ultra Rare Genetic Disease Candidate
24 Aug, 2021 FinancialContent

Stealth BioTherapeutics Corp(NASDAQ: MITO) hassubmitted an elamipretide marketing applicationto the FDA for Barth ...

Stealth BioTherapeutics Submits Elamipretide New Drug Application to FDA for Treatment of Barth Syndrome
24 Aug, 2021 Yahoo! Finance

Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Adminstration (FDA) for elamipretide, the company's lead product candidate, for the treatment of Barth syndrome, an ultra-rare genetic condition with no FDA- or EMA-approved therapies.

Stealth BioTherapeutics Strengthens IP Portfolio with Issuance of U.S. Patents Covering Elamipretide for Barth Syndrome
23 Aug, 2021 Yahoo! Finance

Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that the United States Patent and Trademark Office has issued patents for Stealth's lead product candidate, elamipretide, in the U.S. covering the treatment of Barth syndrome and Barth syndrome-related cardiomyopathy until February 2034.

12 Health Care Stocks Moving In Friday's After-Market Session
20 Aug, 2021 FinancialContent

Gainers CASI Pharmaceuticals (NASDAQ:CASI) shares moved upwards by 12.4% to $1.45 during Friday's after-market session. This ...

Stealth BioTherapeutics to Present at H.C. Wainwright Ophthalmology Virtual Healthcare Conference
11 Aug, 2021 Yahoo! Finance

Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCarthy, CEO, will present at the H.C. Wainwright Ophthalmology Virtual Conference on Tuesday, August 17, 2021 at 7:00 a.m. ET. Additionally, Stealth's management will also participate in H.C. Wainwright's "Addressing Unmet Medical Needs in Macular Degenerat

The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
05 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Stealth BioTherapeutics Reports Second Quarter 2021 Financial Results And Recent Business Highlights
05 Aug, 2021 Yahoo! Finance

Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today reported financial results for the three months ended June 30, 2021 and announced recent business highlights.

30 Stocks Moving in Wednesday's Pre-Market Session
04 Aug, 2021 FinancialContent

Gainers Alterity Therapeutics Limited (NASDAQ: ATHE) shares rose 34.8% to $1.84 in pre-market trading after gaining around 3% on ...

The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
01 Aug, 2021 FinancialContent

Biotech stocks showed a lack of direction in the week endingJuly 30 amid earnings releases from big pharma companies. Most ...

Stealth BioTherapeutics to Report Second Quarter Financial Results on Thursday, August 5
30 Jul, 2021 Yahoo! Finance

Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it will report second quarter 2021 financial results on Thursday, August 5, before the market opens.

Stealth BioTherapeutics (MITO) Sees Hammer Chart Pattern: Time to Buy?
08 Jul, 2021 Yahoo! Finance

Stealth BioTherapeutics (MITO) has been struggling lately, but the selling pressure may be coming to an end soon.

Stealth BioTherapeutics Corp (MITO) is a NASDAQ Common Stock listed in , ,

970x250